Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Humana Inc is a healthcare plans business based in the US. Humana shares (HUM) are listed on the NYSE and all prices are listed in US Dollars. Humana employs 48,700 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$400.75|
|52-week range||$369.03 - $474.69|
|50-day moving average||$411.99|
|200-day moving average||$428.99|
|Wall St. target price||$486.29|
|Dividend yield||$2.65 (0.66%)|
|Earnings per share (TTM)||$18.91|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-15)||-0.06%|
|1 month (2021-08-20)||-3.11%|
|3 months (2021-06-22)||-8.03%|
|6 months (2021-03-22)||-0.90%|
|1 year (2020-09-22)||3.62%|
|2 years (2019-09-20)||44.53%|
|3 years (2018-09-21)||18.65%|
|5 years (2016-09-22)||127.71%|
Valuing Humana stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Humana's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Humana's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Humana shares trade at around 22x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Humana's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2253. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Humana's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Humana's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.2 billion.
The EBITDA is a measure of a Humana's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$80.5 billion|
|Operating margin TTM||4.89%|
|Gross profit TTM||$15.5 billion|
|Return on assets TTM||6.43%|
|Return on equity TTM||16.97%|
|Market capitalisation||$52.4 billion|
TTM: trailing 12 months
There are currently 1.9 million Humana shares held short by investors – that's known as Humana's "short interest". This figure is 22.3% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Humana shares can be evaluated.
Humana's "short interest ratio" (SIR) is the quantity of Humana shares currently shorted divided by the average quantity of Humana shares traded daily (recently around 750977.34375). Humana's SIR currently stands at 2.56. In other words for every 100,000 Humana shares traded daily on the market, roughly 2560 shares are currently held short.
However Humana's short interest can also be evaluated against the total number of Humana shares, or, against the total number of tradable Humana shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Humana's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Humana shares in existence, roughly 20 shares are currently held short) or 0.015% of the tradable shares (for every 100,000 tradable Humana shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Humana.
Find out more about how you can short Humana stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Humana.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 25.71
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Humana's overall score of 25.71 (as at 12/31/2018) is pretty good – landing it in it in the 33rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Humana is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.6/100
Humana's environmental score of 2.6 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Humana is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 18.54/100
Humana's social score of 18.54 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Humana is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.07/100
Humana's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Humana is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Humana scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Humana has, for the most part, managed to keep its nose clean.
|Total ESG score||25.71|
|Total ESG percentile||32.96|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||2|
Dividend payout ratio: 17.76% of net profits
Recently Humana has paid out, on average, around 17.76% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.7% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Humana shareholders could enjoy a 0.7% return on their shares, in the form of dividend payments. In Humana's case, that would currently equate to about $2.65 per share.
While Humana's payout ratio might seem low, this can signify that Humana is investing more in its future growth.
Humana's most recent dividend payout was on 28 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 28 September 2021 (the "ex-dividend date").
Humana's shares were split on a 3:2 basis on 31 July 1991. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Humana shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Humana shares which in turn could have impacted Humana's share price.
Over the last 12 months, Humana's shares have ranged in value from as little as $369.0291 up to $474.6919. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Humana's is 0.8886. This would suggest that Humana's shares are less volatile than average (for this exchange).
Humana Inc. , together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.